Hyperthyroidism can cause individuals to experience unexplained weight loss due to increased metabolism, despite a normal or increased appetite
Its triple-receptor activation suggests it could redefine obesity and diabetes management, offering a more comprehensive approach than previous peptide therapeutics
Wang K, Hu J, Luo T, et al
Semaglutide GLP-1 may not be appropriate for everyone, especially those with a history of severe gastrointestinal problems, active pancreatitis, certain thyroid cancers, multiple endocrine neoplasia syndrome type 2, severe eating disorders, or a history of medullary thyroid carcinoma in ones family or personal
1,3 A 2025 systematic review in the International Journal of Dermatology confirmed that among GLP-1 receptor agonists, semaglutide and tirzepatide showed the highest reported incidence of hair loss, with telogen effluvium and androgenetic alopecia (AGA) identified as the predominant subtypes
